CVS Health Corporation revealed on Wednesday that its revenue in the fourth quarter of fiscal 2024 stood at $97.7 billion, increasing by 4.2% year-on-year and surpassing analysts' estimates. Diluted earnings per share dropped by 17% on a yearly basis to $1.30. Operating income was $2.3 billion, falling by 29% from the same period in 2023.
For the 2025 guidance, the healthcare company expects diluted EPS between $4.58 to $4.83 while cash flow from operations is forecast at approximately $6.5 billion.
"We have continued to see growth in key areas of our business, including the Pharmacy and Consumer Wellness segment, while we address the industry-wide challenges that have impacted our Health Care Benefits segment. Through the continued dedication of our colleagues, we will be positioned for strong performance in 2025 as we deliver simply better care for consumers while improving outcomes and reducing costs," CEO David Joyner stated. The company's shares surged by 9.15% during premarket trading after the report was released to sell for $60.03 at 6:36 am ET.
